{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:25:41Z","timestamp":1765974341454},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,25]]},"DOI":"10.18632\/oncotarget.15115","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T22:46:44Z","timestamp":1486421204000},"page":"27772-27785","source":"Crossref","is-referenced-by-count":7,"title":["An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Min-Wu","family":"Chao","sequence":"first","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Li","family":"Huang","sequence":"additional","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Min","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"The Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Jung","family":"Lai","sequence":"additional","affiliation":[{"name":"Translational Research Center, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Ming","family":"Teng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan"},{"name":"Pharmacological Institute, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ron","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.emc.2014.04.004","article-title":"Acute leukemia","volume":"32","author":"Kuehl","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","article-title":"Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia","volume":"21","author":"Douer","year":"2016","journal-title":"Oncologist"},{"key":"3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.critrevonc.2015.12.007","article-title":"Clinical updates in adult acute lymphoblastic leukemia","volume":"99","author":"Wetzler","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult Acute Lymphoblastic Leukemia","volume":"91","author":"Jabbour","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Jordan","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1517\/13543776.2014.859247","article-title":"Tubulin inhibitors: a patent review","volume":"24","author":"Liou","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Johnston","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2005.09.010","article-title":"Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR)","volume":"32","author":"Menefee","year":"2005","journal-title":"Semin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.bjc.6602902","article-title":"mTOR signaling: implications for cancer and anticancer therapy","volume":"94","author":"Sonenberg","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Bouscary","year":"2010","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Raymond","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ejmech.2009.12.013","article-title":"Synthesis,antibacterial and antifungal evaluations of new alpha-hydroxyphosphonate and new alpha-acetoxyphosphonate derivatives of tetrazolo [1, 5-a] quinoline","volume":"45","author":"Shingare","year":"2010","journal-title":"Eur J Med Chem"},{"key":"13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bmcl.2004.10.037","article-title":"Design, synthesis and evaluation of 5-substituted amino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as novel antimalarials","volume":"15","author":"Viswanathan","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.bmcl.2010.01.001","article-title":"Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum","volume":"20","author":"Roncal","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Gopaul, Shintre, Koorbanally. A Review on the Synthesis and Anti-Cancer Activity of 2-Substituted Quinolines. Anticancer Agents Med Chem. 2014.","DOI":"10.1002\/chin.201538256"},{"key":"16","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1016\/j.bmc.2006.06.020","article-title":"Synthesis andantitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(\u2212thiourea) pharmacophores, and some derived thiazole ring systems","volume":"14","author":"Rostom","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lo, Chou, Tseng, Shiu, Chen, Yang, Chen, Lin, Tzeng. Discovery of Novel N-Alkyl 4-Anilinofuro[2,3-b]Quinoline Derivatives (CIL-102 Derivatives) Against Castration-Resistant Human Prostate Cancers. Anticancer Agents Med Chem. 2015.","DOI":"10.2174\/1871520615666150121122700"},{"key":"18","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Kroemer","year":"2004","journal-title":"Oncogene"},{"key":"19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10555-009-9184-9","article-title":"Mitotic drivers\u2014inhibitors of the Aurora B Kinase","volume":"28","author":"Taylor","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00280-005-0111-7","article-title":"Role of mitochondria as the gardens of cell death","volume":"57","author":"Tanabe","year":"2006","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"21","doi-asserted-by":"publisher","first-page":"25255","DOI":"10.1074\/jbc.M909826199","article-title":"MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain","volume":"275","author":"Hsueh","year":"2000","journal-title":"J Biol Chem"},{"key":"22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.onc.1204062","article-title":"Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53","volume":"20","author":"Seger","year":"2001","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/excr.1999.4731","article-title":"Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells","volume":"254","author":"Chambers","year":"2000","journal-title":"Exp Cell Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.ccr-10-0480","article-title":"Target of Rapamycin Signaling in Leukemia and Lymphoma","volume":"16","author":"Fruman","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Park, Chapuis, Tamburini, Bardet, Cornillet-Lefebvre, Willems, Green, Mayeux, Lacombe, Bouscary. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010.","DOI":"10.3324\/haematol.2009.013797"},{"key":"26","first-page":"5342","article-title":"Expression of multidrug resistance-associated protein in NIH\/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution","volume":"55","author":"Kruh","year":"1995","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"21020","DOI":"10.1016\/S0021-9258(19)36791-2","article-title":"Characterization of the azidopine and vinblastine binding site of P-glycoprotein","volume":"267","author":"Pastan","year":"1992","journal-title":"J Biol Chem"},{"key":"28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ijc.21013","article-title":"MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid","volume":"116","author":"Schinkel","year":"2005","journal-title":"Int J Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Wilson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1186\/1471-2105-12-s1-s33","article-title":"iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis","volume":"12","author":"Yang","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrm2105","article-title":"Multiple levels of cyclin specificity in cell-cycle control","volume":"8","author":"Cross","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"32","doi-asserted-by":"publisher","first-page":"15359","DOI":"10.1074\/jbc.R900005200","article-title":"Kinase signaling in the spindle checkpoint","volume":"284","author":"Yu","year":"2009","journal-title":"J Biol Chem"},{"key":"33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1124\/mi.11.2.12","article-title":"Spindle poisons and cell fate: a tale of two pathways","volume":"11","author":"Stukenberg","year":"2011","journal-title":"Mol Interv"},{"key":"34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2402090","article-title":"Phosphorylation of Bcl2 and regulation of apoptosis","volume":"15","author":"May","year":"2001","journal-title":"Leukemia"},{"key":"35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"O\u2019Rourke","year":"2011","journal-title":"Nature"},{"key":"36","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1038\/cddis.2013.360","article-title":"Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death","volume":"4","author":"Chambers","year":"2013","journal-title":"Cell Death Dis"},{"issue":"23","key":"37","first-page":"2838","article-title":"Mitogen-activated protein kinases in apoptosis regulation","volume":"0000","author":"Penninger","journal-title":"Oncogene"},{"key":"38","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1128\/MCB.19.12.8469","article-title":"BCL-2 Is Phosphorylated and Inactivated by an ASK1\/Jun N-Terminal Protein Kinase Pathway Normally Activated at G(2)\/M","volume":"19","author":"Korsmeyer","year":"1999","journal-title":"Molecular and Cellular Biology"},{"key":"39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"mTOR Inhibitors and Their Potential Role in Therapy in Leukemia and Other Haematologic Malignancies","volume":"145","author":"Brown","year":"2009","journal-title":"British journal of haematology"},{"key":"40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/sj.bjc.6603353","article-title":"Predicted mechanisms of resistance to mTOR inhibitors","volume":"95","author":"Houghton","year":"2006","journal-title":"Br J Cancer"},{"key":"41","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/jco.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Kaufmann","year":"2005","journal-title":"J Clin Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/ijc.28206","article-title":"Concurrent inhibition of PI3K and mTORC1\/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma","volume":"133","author":"Scholz","year":"2013","journal-title":"Int J Cancer"},{"key":"43","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Bendall","year":"2009","journal-title":"Blood"},{"key":"44","doi-asserted-by":"publisher","first-page":"e44093","DOI":"10.1371\/journal.pone.0044093","article-title":"alpha-Tomatine-mediated anti-cancer activityandthrough cell cycle- and caspase-independent pathways","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS One"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T17:02:29Z","timestamp":1658595749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":44,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,4,25]]}},"alternative-id":["15115","28186963"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15115","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]}}}